Editorial: Lucky Number 8!


Opening our doors a little wider

Now in our eighth volume, ChemMedChem is still considered to be quite a young journal, yet the first full five-year impact factor of 3.445 (Thomson ISI 2011 Journal Citation Report) shows that articles published in the journal already have lasting importance. Of course, we will look to increase our standing in the coming year, and to do so, the journal must not only maintain the high standards already in place, but it must also evolve in parallel with the field.

Both in industry and academia, the interdisciplinary nature of drug discovery necessitates a broad definition of medicinal chemistry. The avenues through which scientists can intervene therapeutically continue to broaden and diversify as their understanding of complex biological systems in disease increases. For example, the identification of bromodomains as therapeutic targets, a current hot topic in the field, has come through an increased understanding of epigenetic processes and their roles in diseases such as cancer. Furthermore, medicinal chemistry is playing a growing role in vaccine development, an area previously dominated by researchers in biological and life sciences, providing another means through which vaccines can be developed. While medicinal chemistry has always had a hand in drug delivery, the increasingly blurred line between chemistry and materials science is also having a knock-on effect, as more and more research groups have expertise in both fields. In short, the scope of ChemMedChem continues to develop and adapt to the needs and wishes of our readers and authors alike, and we welcome exciting contributions that might have previously been considered on the peripheries of medicinal chemistry in a traditional sense.

Crunching numbers

ChemMedChem continues to stand out in terms of editorial office efficiency, which is an ever-increasingly important feature in today′s climate of rapid publication and electronic information. The time taken for peer review (i.e., from manuscript submission to the initial decision) was typically between 19 and 26 days for 2012 (Jan–Nov). We continually strive to shorten this time, within reason of course, and our default has been, and will continue to be, to ask referees to complete their review within two weeks of receipt of our request. The additional week in our average values stems from the obvious fact that our referees have many other commitments, sometimes requiring additional time or declining to provide comments altogether. Our goal of getting this average value a bit closer to a very author-friendly two weeks is tempered by allowing our referees enough time to carry out meaningful and thorough peer review.

Our publication times continue to be impressive. From submission to online publication in Early View, the average time taken is 65 days (Jan–Nov 2012), with the majority of this time taken in peer review or author revision. Interestingly, the average publication time for a Communication is around 10 days quicker, ensuring that research results presented in this article format reach the community in record time. Of course, we will continue to streamline our production processes to ensure the rapid and seamless production of the final article while maintaining our high standard of presentation and service to our authors.

Our acceptance rate is currently at around 35–40 %. Given the number of manuscripts we receive for evaluation, the efforts of our referees cannot be overemphasized here. Their continued support of ChemMedChem by providing timely and insightful critiques helps ensure that only the most interesting and impactful research is published in the journal (Tables 1 and 2), and that all authors receive constructive comments for the improvement of their manuscript, whether for publication in ChemMedChem or elsewhere.

Table 1. The top-ten most cited ChemMedChem articles of 2011.[a]

First Author


Times Cited[b]




  1. [a] January–December 2011. [b] Data from Thompson ISI. [c] C=Communication, F=Full Paper, R=Review. [d] Volume(issue), first page. [e] Digital object identifiers (DOIs) can be resolved at http://dx.doi.org.

R. Abel

Contribution of Explicit Solvent Effects to the Binding Affinity of Small- Molecule Inhibitors in Blood Coagulation Factor Serine Proteases



6(6), 1049


F. Oulaidi

Second-Generation Iminoxylitol-Based Pharmacological Chaperones for the Treatment of Gaucher Disease



6(2), 353


K. P. Chan

Chemical Synthesis and Biological Evaluation of the Englerin Analogues



6(3), 420


E. J. Keliher

High-Yielding, Two-Step 18F Labeling Strategy for 18F-PARP1 Inhibitors



6(3), 424


S. R. LaPlante

Revealing Atropisomer Axial Chirality in Drug Discovery



6(3), 505


L. Q. Al-Mawsawi

Allosteric Inhibitor Development Targeting HIV-1 Integrase



6(2), 228


S. Messaoudi

Discovery of Isoerianin Analogues as Promising Anticancer Agents



6(3), 488


R. K. Haynes

Reactions of Antimalarial Peroxides with Each of Leucomethylene Blue and Dihydroflavins: Flavin Reductase and the Cofactor Model Exemplified



6(2), 279


S. Komeda

A Tetrazolato-Bridged Dinuclear Platinum(II) Complex Exhibits Markedly High in vivo Antitumor Activity against Pancreatic Cancer



6(6), 987


J. M. Dabrowski

Biodistribution and Photodynamic Efficacy of a Water-Soluble, Stable, Halo- genated Bacteriochlorin against Melanoma



6(3), 465


Table 2. The top-ten most accessed ChemMedChem articles from October 2011 to September 2012.

First Author





  1. [a] C=Communication, F=Full Paper, M=Minireview, R=Review. [b] Year, volume, first page. [c] Digital object identifiers (DOIs) can be resolved at http://dx.doi.org.

S. Peukert

Small-Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer Therapeutics


2010, 5, 500


F. Kratz

Prodrug Strategies in Anticancer Chemotherapy


2008, 3, 20


S. R. LaPlante

Revealing Atropisomer Axial Chirality in Drug Discovery


2011, 6, 505


J. L. Yap

Small-Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anti- cancer Therapeutics


2011, 6, 38


K. Zhang

A Novel Aptamer Developed for Breast Cancer Cell Internalization


2012, 7, 79


T.-m. Ou

G-Quadruplexes: Targets in Anticancer Drug Design


2008, 3, 690


N. Gavande

Identification of Benzopyran-4-one Derivatives (Isoflavones) as Positive Modulators of GABAA Receptors


2011, 6, 1340


Z. Pan

Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase


2007, 2, 58


K.-H. Chang

Inhibition of Histone Demethylases by 4-Carboxy-2,2′-Bi-pyridyl Compounds


2011, 6, 759


E. Jacoby

The 7 TM G-Protein-Coupled Receptor Target Family


2006, 1, 760


Interestingly, the profile for 2012 manuscript submissions by region changed this year, with China and the US now in front, accounting for 15 % and 13 % of this year′s submissions, respectively. Italy (10 %) and Germany (8 %) still had a strong showing, but the fact that these traditional frontrunner spots are now occupied by Asian and North American submission rates reflects the increased global appeal of ChemMedChem.

On average, our publication time, from submission to online publication in Early View, is 65 days…the average publication time for a Communication is around 10 days quicker…

Keeping your options open

Open access remains a hot topic in the scientific community. While much of the debate is beyond the scope of this Editorial, the increasing number of funding agencies mandating the open-access publication of research results means that our authors occasionally need an open-access option. While ChemMedChem is a subscription-based journal, OnlineOpen enables an author to make their article available to nonsubscribers through the payment of a one-off article publication charge (for more details, see www.chemmedchem.org/open).

Thumbnail image of

While OnlineOpen is an appropriate solution for most, some funders require that the article is published in a fully open-access forum, and for this we would recommend our new sister journal, ChemistryOpen. Now in its second volume, this society-owned general chemistry journal is overturning the preconception that open-access journals are low quality. For more details, see the journal homepage: www.chemistryopen.org or contact the Editorial Office directly: chemistryopen@wiley-vch.de.

Birthdays worth celebrating

Thumbnail image of

Angewandte Chemie is now in its 125th year of publication. To commemorate this landmark volume, the German Chemical Society (GDCh), the journal owners, together with its publishers Wiley-VCH, are holding an Anniversary Symposium in Berlin on Tuesday March 12, 2013. With presentations from numerous high-profile scientists including three Nobel Prize laureates, the symposium promises to be as high-impact and interesting as the journal itself. For more details, visit http://angewandte.org/symposium; registration is open until February 12th.

Thumbnail image of

Wiley-VCH is known for its strong book program, particularly in medicinal chemistry, and the familiar blue and white covers will no doubt be visible on your book shelf or those of your library. 2012 marked the 25th anniversary of this brand, which through periodic modernization has continued to publish timely works from field leaders. Some recent or upcoming medicinal chemistry titles include: Analogue-Based Drug Discovery III edited by Janos Fischer, C. Robin Ganellin and David P. Rotella (ISBN: 978-3-527-33073-7), Protein–Protein Interactions in Drug Discovery edited by Alexander Dömling (ISBN: 978-3-527-33107-9), Antimicrobial Peptides authored by David A. Phoenix, Sarah Dennison and Fred Harris (ISBN: 978-3-527-33263-2), and Antibiotics—Targets, Mechanism and Resistance edited by Claudio O. Gualerzi, Letizia Brandi, Attilio Fabbretti and Cynthia L. Pon (ISBN: 978-3-527-33305-9).

We′ll be seeing you

Conferences are a unique opportunity for us to meet our authors, reviewers, board members, and readers alike. We try and attend as many conferences as is practical over the course of a year, largely to ensure we keep our fingers on the pulse of the community we serve. In 2012, we had the pleasure of attending major events such as the Spring ACS National Meeting held in San Diego, and the ISMC 2012 in Berlin where we also produced the Book of Abstracts. Looking ahead, the 11th Winter Conference on Bioorganic and Medicinal Chemistry (Steamboat Springs, USA), the EFMC/ACS Frontiers in Medicinal Chemistry meeting in San Francisco, and the AFMC International Medicinal Chemistry Symposium (AIMECS) in Taipei are all in our calendar, and we hope to see you there.

And finally…

All that remains to be said is happy New Year and all the best with your research in 2013. We hope you will continue to read ChemMedChem and consider it an invaluable resource for quality research articles. And of course, we look forward to receiving your next high-impact manuscript!

Thumbnail image of

Dr. Natalia Ortúzar



Thumbnail image of

Dr. Scott D. Williams

Sr. Assoc. Editor ChemMedChem